High Quality Content by WIKIPEDIA articles! Vortioxetine (Lu AA21004) is an experimental drug currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is a so-called "serotonin modulator and stimulator", and acts as a serotonin transporter blocker (Ki = 1.6 nM), 5-HT1A receptor near-full agonist (Ki = 15 nM; IA = 80%), 5-HT1B receptor partial agonist (Ki = 33 nM), 5-HT3A receptor antagonist (Ki = 3.7 nM), and 5-HT7 receptor antagonist (Ki = 19 nM). It also has affinity for the ?1-adrenergic receptor (Ki = 46 nM), though its intrinsic activity at this site is not yet known. In 2009, vortioxetine began phase III clinical trials. In a double-blind, randomized, placebo-controlled clinical trial with venlafaxine as an active reference, it was found to be efficacious in treating MDD, while having fewer side effects than its comparator. A New Drug Application (NDA) is not expected to be submitted to the...

В наличии:
	Books.Ru - 1258 руб.	Перейти
Под заказ:
	OZON.ru - 1254 руб.	Перейти

Рейтинг книги: 5 из 5, 10 голос(-ов).